+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Supportive Care Products Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 212 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5916031
The global prevalence of cancer is on the rise, with more than 24 million cancer cases projected worldwide by 2035, according to the World Cancer Research Fund International (WCRF). This alarming trend has spurred healthcare organizations and governments to take action, leading to a significant increase in demand for products that support cancer care.

In addition to the growing incidence of cancer, the global cancer supportive care products market is being driven by several factors:

1. Aging Population: The world's aging population is increasing, leading to a higher demand for cancer care and supportive products.

2. Advancements in Anti-Cancer Treatments: The effectiveness of anti-cancer treatments has improved, leading to an increased need for supportive care products to manage side effects.

3. Growing Urban Population: The urban population in emerging economies has greater purchasing power, contributing to increased demand for cancer supportive care products.

4. Product Innovation: Ongoing innovation in cancer supportive care products is driving market growth, with companies continually developing new and improved solutions.

Despite these positive factors, the market faces some challenges:

1. Entry of Biosimilars: The entry of biosimilars poses a challenge to the market, impacting the sales of branded cancer supportive care products.

2. High R&D Costs: The extremely high cost of research and development practices is a significant barrier to market growth.

3. Regulatory Barriers: Regulatory barriers can slow down product approvals and market entry.

However, there are opportunities for market vendors, particularly in the highly populated emerging economies of Asia Pacific, where increased investments in research and development can drive growth.

Key Drug Classes in Demand

The cancer supportive care products market is segmented into various drug classes, including opioid analgesics, nonsteroidal erythropoietin stimulating agents, anti-infective drugs, anti-inflammatory drugs, bisphosphonates, monoclonal antibodies, anti-emetics drugs, and granulocyte colony-stimulating factor. Among these, erythropoietin stimulating agents and granulocyte colony-stimulating factor are expected to account for a significant portion of demand.

Lung and Breast Cancer Lead Demand

In terms of indications, lung cancer and breast cancer are expected to lead in demand for cancer supportive care products. Several governments have initiated awareness campaigns focusing on these two types of cancer, driving growth in these segments.

Distribution Channels

The market is distributed through various channels, including hospital pharmacies, compounding pharmacies, and retail pharmacies. Each channel plays a crucial role in reaching patients and healthcare providers.

Global Outlook

While North America boasts a robust healthcare infrastructure and high adoption of new technology, Asia Pacific, particularly China and India, offers promising opportunities due to the rapidly increasing disposable income among the urban population.

The global cancer supportive care products market is poised for continued growth as the prevalence of cancer continues to rise, and healthcare organizations strive to meet the growing demand for supportive care.


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Cancer Supportive Care Products Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. Pestle Analysis
3. Global Cancer Supportive Care Products Market Outlook, 2018 - 2031
3.1. Global Cancer Supportive Care Products Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Nonsteroidal Anti-inflammatory Drugs
3.1.1.2. Anti-infective
3.1.1.3. Anti-emetics
3.1.1.4. Monoclonal Antibodies
3.1.1.5. Erythropoietin Stimulating Agents
3.1.1.6. Opioid Analgesics
3.1.1.7. Bisphosphonates
3.1.1.8. Granulocyte Colony Stimulating Factor
3.2. Global Cancer Supportive Care Products Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Lung Cancer
3.2.1.2. Breast Cancer
3.2.1.3. Liver Cancer
3.2.1.4. Bladder Cancer
3.2.1.5. Leukaemia
3.2.1.6. Ovarian Cancer
3.2.1.7. Melanoma
3.2.1.8. Other Cancer
3.3. Global Cancer Supportive Care Products Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Compounding Pharmacies
3.4. Global Cancer Supportive Care Products Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Cancer Supportive Care Products Market Outlook, 2018 - 2031
4.1. North America Cancer Supportive Care Products Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Nonsteroidal Anti-inflammatory Drugs
4.1.1.2. Anti-infective
4.1.1.3. Anti-emetics
4.1.1.4. Monoclonal Antibodies
4.1.1.5. Erythropoietin Stimulating Agents
4.1.1.6. Opioid Analgesics
4.1.1.7. Bisphosphonates
4.1.1.8. Granulocyte Colony Stimulating Factor
4.2. North America Cancer Supportive Care Products Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Lung Cancer
4.2.1.2. Breast Cancer
4.2.1.3. Liver Cancer
4.2.1.4. Bladder Cancer
4.2.1.5. Leukaemia
4.2.1.6. Ovarian Cancer
4.2.1.7. Melanoma
4.2.1.8. Other Cancer
4.3. North America Cancer Supportive Care Products Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Compounding Pharmacies
4.3.2. Bps Analysis/Market Attractiveness Analysis
4.4. North America Cancer Supportive Care Products Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
4.4.2. Bps Analysis/Market Attractiveness Analysis
5. Europe Cancer Supportive Care Products Market Outlook, 2018 - 2031
5.1. Europe Cancer Supportive Care Products Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Nonsteroidal Anti-inflammatory Drugs
5.1.1.2. Anti-infective
5.1.1.3. Anti-emetics
5.1.1.4. Monoclonal Antibodies
5.1.1.5. Erythropoietin Stimulating Agents
5.1.1.6. Opioid Analgesics
5.1.1.7. Bisphosphonates
5.1.1.8. Granulocyte Colony Stimulating Factor
5.2. Europe Cancer Supportive Care Products Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Lung Cancer
5.2.1.2. Breast Cancer
5.2.1.3. Liver Cancer
5.2.1.4. Bladder Cancer
5.2.1.5. Leukaemia
5.2.1.6. Ovarian Cancer
5.2.1.7. Melanoma
5.2.1.8. Other Cancer
5.3. Europe Cancer Supportive Care Products Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Compounding Pharmacies
5.3.2. Bps Analysis/Market Attractiveness Analysis
5.4. Europe Cancer Supportive Care Products Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.1.7. France Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.8. France Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.9. France Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest Of Europe Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest Of Europe Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest Of Europe Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.4.2. Bps Analysis/Market Attractiveness Analysis
6. Asia Pacific Cancer Supportive Care Products Market Outlook, 2018 - 2031
6.1. Asia Pacific Cancer Supportive Care Products Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Nonsteroidal Anti-inflammatory Drugs
6.1.1.2. Anti-infective
6.1.1.3. Anti-emetics
6.1.1.4. Monoclonal Antibodies
6.1.1.5. Erythropoietin Stimulating Agents
6.1.1.6. Opioid Analgesics
6.1.1.7. Bisphosphonates
6.1.1.8. Granulocyte Colony Stimulating Factor
6.2. Asia Pacific Cancer Supportive Care Products Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Lung Cancer
6.2.1.2. Breast Cancer
6.2.1.3. Liver Cancer
6.2.1.4. Bladder Cancer
6.2.1.5. Leukaemia
6.2.1.6. Ovarian Cancer
6.2.1.7. Melanoma
6.2.1.8. Other Cancer
6.3. Asia Pacific Cancer Supportive Care Products Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Compounding Pharmacies
6.3.2. Bps Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Cancer Supportive Care Products Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
6.4.1.2. China Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.3. China Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.4.1.10. India Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
6.4.1.11. India Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.12. India Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest Of Asia Pacific Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest Of Asia Pacific Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest Of Asia Pacific Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.4.2. Bps Analysis/Market Attractiveness Analysis
7. Latin America Cancer Supportive Care Products Market Outlook, 2018 - 2031
7.1. Latin America Cancer Supportive Care Products Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Nonsteroidal Anti-inflammatory Drugs
7.1.1.2. Anti-infective
7.1.1.3. Anti-emetics
7.1.1.4. Monoclonal Antibodies
7.1.1.5. Erythropoietin Stimulating Agents
7.1.1.6. Opioid Analgesics
7.1.1.7. Bisphosphonates
7.1.1.8. Granulocyte Colony Stimulating Factor
7.2. Latin America Cancer Supportive Care Products Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Lung Cancer
7.2.1.2. Breast Cancer
7.2.1.3. Liver Cancer
7.2.1.4. Bladder Cancer
7.2.1.5. Leukaemia
7.2.1.6. Ovarian Cancer
7.2.1.7. Melanoma
7.2.1.8. Other Cancer
7.3. Latin America Cancer Supportive Care Products Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Compounding Pharmacies
7.3.2. Bps Analysis/Market Attractiveness Analysis
7.4. Latin America Cancer Supportive Care Products Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest Of Latin America Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest Of Latin America Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest Of Latin America Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.4.2. Bps Analysis/Market Attractiveness Analysis
8. Middle East & Africa Cancer Supportive Care Products Market Outlook, 2018 - 2031
8.1. Middle East & Africa Cancer Supportive Care Products Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Nonsteroidal Anti-inflammatory Drugs
8.1.1.2. Anti-infective
8.1.1.3. Anti-emetics
8.1.1.4. Monoclonal Antibodies
8.1.1.5. Erythropoietin Stimulating Agents
8.1.1.6. Opioid Analgesics
8.1.1.7. Bisphosphonates
8.1.1.8. Granulocyte Colony Stimulating Factor
8.2. Middle East & Africa Cancer Supportive Care Products Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Lung Cancer
8.2.1.2. Breast Cancer
8.2.1.3. Liver Cancer
8.2.1.4. Bladder Cancer
8.2.1.5. Leukaemia
8.2.1.6. Ovarian Cancer
8.2.1.7. Melanoma
8.2.1.8. Other Cancer
8.3. Middle East & Africa Cancer Supportive Care Products Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Compounding Pharmacies
8.3.2. Bps Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Cancer Supportive Care Products Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest Of Middle East & Africa Cancer Supportive Care Products Market by Drug Class, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest Of Middle East & Africa Cancer Supportive Care Products Market by Indication, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest Of Middle East & Africa Cancer Supportive Care Products Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.4.2. Bps Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel Vs by Indication Heat Map
9.2. Manufacturer Vs by Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Amgen Inc.
9.5.1.1. Company Overview
9.5.1.2. Drug Class Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Johnson & Johnson Private Ltd.
9.5.2.1. Company Overview
9.5.2.2. Drug Class Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Novartis AG
9.5.3.1. Company Overview
9.5.3.2. Drug Class Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Baxter International Inc
9.5.4.1. Company Overview
9.5.4.2. Drug Class Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Hoffmann-La Roche Ltd.
9.5.5.1. Company Overview
9.5.5.2. Drug Class Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Fagron Group BV
9.5.6.1. Company Overview
9.5.6.2. Drug Class Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Teva Pharmaceutical Industries Ltd.
9.5.7.1. Company Overview
9.5.7.2. Drug Class Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms And Abbreviations

Companies Mentioned

  • Amgen Inc.
  • Johnson & Johnson.
  • Novartis Ag.
  • Baxter International Inc.
  • Fagron Group BV.
  • Teva Pharmaceuticals Industries Ltd.
  • Hoffmann LA- Roche Inc.
  • APR Applied Pharma Science Research S.A.
  • Acacia Pharma Ltd.
  • Kyowa Hakko Kirin Co Ltd.
  • Other.

Methodology

Loading
LOADING...